Company Intelligence

Due diligence intelligence for active companies. Signal-scored across geopolitical exposure, regulatory risk, and sector tailwinds — ranked by composite risk/opportunity score.

Filters:🇺🇸 United States ✕

All energy technology financials healthcare industrials consumer materials utilities defense semiconductors mining pharma telecom shipping agriculture real_estate

All postures ✦ Opportunities ⚠ Risks

Themes for pharma

💊Pharma Supply Chain Reshoring

Total Tracked

Opportunities

Risk Flags

No data

✦

Opportunities

(0)

Ticker

Company

Sector

Action

Flag

Score

No opportunities in this filter

⚠

Risks

(3)

Ticker

Company

Sector

Action

Flag

Score

REGN

🇺🇸Regeneron Pharmaceuticals Inc.

Regeneron's Eylea HD launch is being squeezed by Roche's Vab

Regeneron's Eylea HD launch is being squeezed by Roche's Vabysmo and incoming aflibercept biosimilar

Regeneron's Eylea HD launch is being squeezed by Roche's Vabysmo and incoming aflibercept biosimilars. Patent litigation against Amgen and S

pharma

AVOID

MRK

🇺🇸Merck & Co. Inc.

Merck's Keytruda patent cliff in 2028 looms larger as oncolo

Merck's Keytruda patent cliff in 2028 looms larger as oncology pipeline replacements underwhelm in t

Merck's Keytruda patent cliff in 2028 looms larger as oncology pipeline replacements underwhelm in trials. The subcutaneous Keytruda formula

pharma

AVOID

🇺🇸

-22—

BMY

🇺🇸Bristol-Myers Squibb Company

BMY faces a compounding patent cliff with Revlimid already e

BMY faces a compounding patent cliff with Revlimid already eroded, Eliquis Medicare negotiation hitt

BMY faces a compounding patent cliff with Revlimid already eroded, Eliquis Medicare negotiation hitting 2026, and Opdivo LOE approaching. Th

pharma

AVOID

🇺🇸

-22—